GW Pharmaceuticals resumed with an Overweight at Morgan Stanley. Morgan Stanley analyst David Lebowitz resumed coverage of GW Pharmaceuticals with an Overweight rating and $197 price target, stating that he expects a strong launch for Epidiolex for Dravet and Lenox-Gastaut syndromes once the DEA has officially rescheduled the marijuana-based therapy as being acceptable for medicinal use. He projects 2019 Epidiolex franchise sales of $72M growing to $1.3B by 2025, Lebowitz tells investors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.